Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report
Novartis and Bristol Myers Squibb have paused trials of their CAR-T cell therapies for autoimmune disorders due to safety concerns. Novartis reported fatal outcomes in three trials of Rap-cel, while Bristol Myers noted reversible inflammatory events in Zola-cel trials. Both companies are reviewing data and engaging with regulators. Analysts suggest faster manufacturing processes may be linked to the issues, affecting multiple biotech companies' stocks.
How this was made
The 30-second read
Why it matters
Both companies face immediate reputational and financial risk, with possible downstream effects on the broader CAR‑T and biotech sectors.
Market read
Trial suspensions introduce short‑term downside risk for the two issuers and may temper enthusiasm for fast‑manufacturing CAR‑T platforms.
What to watch
Potential competitive advantage of faster manufacturing may still attract investors if safety is resolved.
Background
The article reports the first public disclosure of trial pauses for two major pharma companies developing CAR‑T therapies for autoimmune diseases.
Ticker impact
Novartis paused eight autoimmune CAR‑T trials after three fatal IEC‑HS events were reported.
downside risk of 3‑5% pending further regulator updates
Trial holds signal safety issues; investors may reassess valuation of the CAR‑T platform.
Bristol Myers Squibb voluntarily paused enrollment in its autoimmune CAR‑T trials after transient inflammatory events.
potential 2‑4% dip until trial resumption details emerge
Enrollment pause introduces uncertainty; market may price in slower progress.
Market effects
Biotech CAR‑T space may see heightened scrutiny of fast‑manufacturing platforms.
US biotech sector could experience slight pullback as safety concerns spread.
International CAR‑T developers may face similar regulatory pressure.
Counterpoint
If safety issues are isolated, the pause could be short‑lived and present a buying opportunity at lower valuations.
Key entities
- CompanyNovartis
Swiss pharma giant developing Rap‑cel CAR‑T therapy.
- CompanyBristol Myers Squibb
US pharma developing Zola‑cel CAR‑T therapy.
- CompanyCabaletta Bio
Biotech competitor in CAR‑T space.
